- Home
- ANEB vs AKTX Comparison
ANEB vs AKTX Comparison
Compare ANEB & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- AKTX
- Stock Information
- Founded
- ANEB 2020
- AKTX N/A
- Country
- ANEB United States
- AKTX United States
- Employees
- ANEB N/A
- AKTX N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- ANEB Health Care
- AKTX Health Care
- Exchange
- ANEB Nasdaq
- AKTX Nasdaq
- Market Cap
- ANEB 36.7M
- AKTX 29.5M
- IPO Year
- ANEB 2021
- AKTX N/A
- Fundamental
- Price
- ANEB $1.46
- AKTX $1.30
- Analyst Decision
- ANEB Buy
- AKTX
- Analyst Count
- ANEB 1
- AKTX 0
- Target Price
- ANEB $8.00
- AKTX N/A
- AVG Volume (30 Days)
- ANEB 6.3K
- AKTX 49.2K
- Earning Date
- ANEB 11-13-2024
- AKTX 11-19-2024
- Dividend Yield
- ANEB N/A
- AKTX N/A
- EPS Growth
- ANEB N/A
- AKTX N/A
- EPS
- ANEB N/A
- AKTX N/A
- Revenue
- ANEB N/A
- AKTX N/A
- Revenue This Year
- ANEB N/A
- AKTX N/A
- Revenue Next Year
- ANEB N/A
- AKTX N/A
- P/E Ratio
- ANEB N/A
- AKTX N/A
- Revenue Growth
- ANEB N/A
- AKTX N/A
- 52 Week Low
- ANEB $1.25
- AKTX $1.08
- 52 Week High
- ANEB $3.30
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- ANEB 36.57
- AKTX 26.66
- Support Level
- ANEB $1.25
- AKTX $1.77
- Resistance Level
- ANEB $1.68
- AKTX $2.45
- Average True Range (ATR)
- ANEB 0.16
- AKTX 0.27
- MACD
- ANEB -0.01
- AKTX -0.10
- Stochastic Oscillator
- ANEB 30.00
- AKTX 13.67
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).